Protective effect of pituitary adenylate cyclase activating polypeptide in diabetic keratopathy

Maugeri, Grazia; D’Amico, Agata Grazia; Magrì, Benedetta; Giunta, Salvatore; Saccone, Salvatore; Federico, Concetta; Bucolo, Claudio; Musumeci, Giuseppe; D’Agata, Velia

doi:10.1016/j.peptides.2023.171107

Cited by 4 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study showed that the expression of PACAP and PAC1R is drastically reduced in the whole cornea of diabetic rats, suggesting that PACAP/PAC1R signaling alteration can concur with the corneal epithelium impairment induced by the hyperglycemic state. The exogenous administration of PACAP, in an in vitro model of DK, characterized by human corneal epithelial cells exposed to sustained levels of high glucose, promoted cell viability, and corneal epithelial wound healing through EGFR/ERK1/2 signaling pathway activation [176]. This mechanism, played by PACAP, confirms the key role of EGFR in corneal epithelial homeostasis [177].…”

Section: Discussionmentioning

confidence: 52%

Involvement of Vasoactive Intestinal Peptide Family Members in Diabetic Keratopathy

Maugeri,

D’Amico,

Magrì

et al. 2024

Applied Sciences

Self Cite

View full text Add to dashboard Cite

Diabetic keratopathy (DK) is a common ocular complication of diabetes, characterized by alteration of the normal wound-healing mechanism, reduction of epithelial hemidesmosomes, disruption of the basement membrane, impaired barrier function, reduced corneal sensitivity, corneal ulcers, and corneal edema. The limited number of clinical studies do not allow a full characterization of the pathophysiology of DK and, until now, effective therapeutic approaches have not been available. However, in recent years, neuropeptides gained great attention for their biochemical characteristics and therapeutic potential. This review focuses on the role of neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the eye and, in particular, in the cornea, in physiological conditions, or during DK, by providing an overview of this diabetes mellitus complication.

show abstract

Section: Discussionmentioning

confidence: 52%